Literature DB >> 20356772

2D binary QSAR modeling of LPA3 receptor antagonism.

James I Fells1, Ryoko Tsukahara, Jianxiong Liu, Gabor Tigyi, Abby L Parrill.   

Abstract

A structurally diverse dataset of 119 compounds was used to develop and validate a 2D binary QSAR model for the LPA(3) receptor. The binary QSAR model was generated using an activity threshold of greater than 15% inhibition at 10 microM. The overall accuracy of the model on the training set was 82%. It had accuracies of 55% for active and 91% for inactive compounds, respectively. The model was validated using an external test set of 10 compounds. The accuracy on the external test set was 60% overall, identifying three out of seven actives and all three inactive compounds. This model was combined with similarity searching to rapidly screen libraries and select 14 candidate LPA(3) antagonists. Experimental assays confirmed 13 of these (93%) met the 15% inhibition threshold defining actives. The successful application of the model to select candidates for screening demonstrates the power of this binary QSAR model to prioritize compound selection for experimental consideration. Copyright (c) 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20356772      PMCID: PMC2873117          DOI: 10.1016/j.jmgm.2010.03.002

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  28 in total

1.  Synthesis and pharmacological evaluation of second-generation phosphatidic acid derivatives as lysophosphatidic acid receptor ligands.

Authors:  Gangadhar G Durgam; Ryoko Tsukahara; Natalia Makarova; Michelle D Walker; Yuko Fujiwara; Kathryn R Pigg; Daniel L Baker; Vineet M Sardar; Abby L Parrill; Gabor Tigyi; Duane D Miller
Journal:  Bioorg Med Chem Lett       Date:  2005-11-02       Impact factor: 2.823

2.  Lysophosphatidic acid binds to and activates GPR92, a G protein-coupled receptor highly expressed in gastrointestinal lymphocytes.

Authors:  Knut Kotarsky; Ake Boketoft; Jesper Bristulf; Niclas E Nilsson; Ake Norberg; Stefan Hansson; Christer Owman; Rannar Sillard; L M Fredrik Leeb-Lundberg; Björn Olde
Journal:  J Pharmacol Exp Ther       Date:  2006-05-01       Impact factor: 4.030

Review 3.  LPA and its analogs-attractive tools for elucidation of LPA biology and drug development.

Authors:  Kuniyuki Kano; Naoaki Arima; Mitsuru Ohgami; Junken Aoki
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

4.  Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.

Authors:  Hideo Ohta; Koichi Sato; Naoya Murata; Alatangaole Damirin; Enkhzol Malchinkhuu; Junko Kon; Takao Kimura; Masayuki Tobo; Yuji Yamazaki; Tomoko Watanabe; Mikio Yagi; Motoko Sato; Rika Suzuki; Hideko Murooka; Teruyuki Sakai; Tsuyoshi Nishitoba; Dong-Soon Im; Hiromi Nochi; Koichi Tamoto; Hideaki Tomura; Fumikazu Okajima
Journal:  Mol Pharmacol       Date:  2003-10       Impact factor: 4.436

5.  Virtual screening approaches for the identification of non-lipid autotaxin inhibitors.

Authors:  Abby L Parrill; Uniqua Echols; Tran Nguyen; Truc-Chi T Pham; Adrienne Hoeglund; Daniel L Baker
Journal:  Bioorg Med Chem       Date:  2007-11-12       Impact factor: 3.641

Review 6.  Biological roles of lysophospholipid receptors revealed by genetic null mice: an update.

Authors:  Ji Woong Choi; Chang-Wook Lee; Jerold Chun
Journal:  Biochim Biophys Acta       Date:  2008-03-25

Review 7.  Biological effects of lysophospholipids.

Authors:  R Rivera; J Chun
Journal:  Rev Physiol Biochem Pharmacol       Date:  2008       Impact factor: 5.545

Review 8.  Lysophospholipid interactions with protein targets.

Authors:  Abby L Parrill
Journal:  Biochim Biophys Acta       Date:  2008-05-02

Review 9.  Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation.

Authors:  Mandi M Murph; Giang H Nguyen; Harish Radhakrishna; Gordon B Mills
Journal:  Biochim Biophys Acta       Date:  2008-04-29

10.  Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo.

Authors:  Honglu Zhang; Xiaoyu Xu; Joanna Gajewiak; Ryoko Tsukahara; Yuko Fujiwara; Jianxiong Liu; James I Fells; Donna Perygin; Abby L Parrill; Gabor Tigyi; Glenn D Prestwich
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

View more
  1 in total

1.  Classification of High-Activity Tiagabine Analogs by Binary QSAR Modeling.

Authors:  Andreas Jurik; Regina Reicherstorfer; Barbara Zdrazil; Gerhard F Ecker
Journal:  Mol Inform       Date:  2013-05-15       Impact factor: 4.050

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.